Novavax (NVAX) Operating Income Growth (1y) (2011 - 2026)
Novavax (NVAX) Operating Income Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 2,150.96% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 145.20% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Novavax | 1.23 Bn | 440.77 Mn | 108.82 Mn | -102.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -102.99% |
| Dec 31, 2025 | 110.86% |
| Sep 30, 2025 | -32.83% |
| Jun 30, 2025 | -37.22% |
| Mar 31, 2025 | 455.94% |
| Dec 31, 2024 | 28.59% |
| Sep 30, 2024 | -6.68% |
| Jun 30, 2024 | 190.31% |
| Mar 31, 2024 | 53.69% |
| Dec 31, 2023 | 24.73% |
| Sep 30, 2023 | 1.22% |
| Jun 30, 2023 | 111.48% |
| Mar 31, 2023 | -249.44% |
| Dec 31, 2022 | 70.44% |
| Sep 30, 2022 | 58.59% |
| Jun 30, 2022 | -39.65% |
| Mar 31, 2022 | 200.32% |
| Dec 31, 2021 | -351.17% |
| Sep 30, 2021 | -58.37% |
| Jun 30, 2021 | -1,931.06% |